252 related articles for article (PubMed ID: 24097332)
1. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.
Germano D; Tinessa V; Barletta E; Cannella L; Daniele B
Drugs Aging; 2013 Nov; 30(11):887-92. PubMed ID: 24097332
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
3. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
4. Targeted Therapy for Hepatocellular Carcinoma.
Ohri N; Kaubisch A; Garg M; Guha C
Semin Radiat Oncol; 2016 Oct; 26(4):338-43. PubMed ID: 27619254
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.
Miyahara K; Nouso K; Yamamoto K
World J Gastroenterol; 2014 Apr; 20(15):4151-9. PubMed ID: 24764653
[TBL] [Abstract][Full Text] [Related]
6. Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
Shin SK; Jung YK; Yoon HH; Kwon OS; Kim YS; Choi DJ; Kim JH
Korean J Gastroenterol; 2014 Jan; 63(1):47-50. PubMed ID: 24463289
[TBL] [Abstract][Full Text] [Related]
7. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
9. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
10. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
Cabibbo G; Maida M; Cammà C; Craxì A
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1355-61. PubMed ID: 24224926
[TBL] [Abstract][Full Text] [Related]
11. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.
Huan HB; Lau WY; Xia F; Ma KS; Bie P
World J Gastroenterol; 2014 Oct; 20(39):14505-9. PubMed ID: 25339839
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
13. Treating advanced hepatocellular carcinoma: How to get out of first gear.
Harding JJ; Abou-Alfa GK
Cancer; 2014 Oct; 120(20):3122-30. PubMed ID: 24898783
[TBL] [Abstract][Full Text] [Related]
14. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Tanoglu A; Karagoz E
Asian Pac J Cancer Prev; 2014; 15(2):1063. PubMed ID: 24568452
[No Abstract] [Full Text] [Related]
16. Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Tong X; Xu X; Shi H; Liu S; Yang Z
PLoS One; 2015; 10(2):e0117168. PubMed ID: 25689846
[TBL] [Abstract][Full Text] [Related]
17. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib: from literature to clinical practice.
Di Marco V; De Vita F; Koskinas J; Semela D; Toniutto P; Verslype C
Ann Oncol; 2013 Apr; 24 Suppl 2():ii30-7. PubMed ID: 23715941
[TBL] [Abstract][Full Text] [Related]
19. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Arizumi T; Ueshima K; Takeda H; Osaki Y; Takita M; Inoue T; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
J Gastroenterol; 2014 Dec; 49(12):1578-87. PubMed ID: 24499826
[TBL] [Abstract][Full Text] [Related]
20. Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
Sun T; Liu H; Ming L
Cell Physiol Biochem; 2017; 44(2):716-727. PubMed ID: 29169150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
